Cytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of pseudomyxoma

Size: px
Start display at page:

Download "Cytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of pseudomyxoma"

Transcription

1 Medical Policy Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pseudomyxoma Peritonei and Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal Mesothelioma Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization Information Policy History Policy Number: 048 BCBSA Reference Number: Related Policies None Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue SM and Medicare PPO Blue SM Members Cytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of pseudomyxoma peritonei may be MEDICALLY NECESSARY. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of diffuse malignant peritoneal mesothelioma may be MEDICALLY NECESSARY. Cytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis from colorectal cancer is INVESTIGATIONAL. Prior Authorization Information Commercial Members: Managed Care (HMO and POS) 1

2 Commercial Members: PPO, and Indemnity Medicare Members: HMO Blue SM Medicare Members: PPO Blue SM CPT Codes / HCPCS Codes / ICD-9 Codes The following codes are included below for informational purposes. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member. Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable. CPT Codes CPT codes: Code Description Chemotherapy administration into the peritoneal cavity via indwelling port or catheter Hyperthermia, externally generated; deep (ie, heating to depths greater than 4 cm) Hyperthermia generated by intracavitary probe(s) ICD-9 Diagnosis Codes ICD-9-CM diagnosis codes: Code Description Malignant neoplasm of retroperitoneum Malignant neoplasm of specified parts of peritoneum Secondary malignant neoplasm of retroperitoneum and peritoneum ICD-9 Procedure Codes When the following ICD 9 procedure codes are associated with the service(s) described in this document coverage for the service(s) is aligned with the policy statement. ICD-9-CM procedure codes: Code Description Implantation of chemotherapeutic agent 54.4 Excision or destruction of peritoneal tissue Hyperthermia for treatment of cancer Description Peritoneal dissemination of tumors of gastrointestinal origin occurs from either the appendix or colon. Malignant mesothelioma is a relatively uncommon malignancy that may arise from the mesothelial cells 2

3 lining the pleura, peritoneum, pericardium, and tunica vaginalis testis. Like tumors of GI origin, mesothelioma may spread to the peritoneal cavity as well. Surgical cytoreduction in conjunction with hyperthermic intraperitoneal chemotherapy is designed to removal visible tumor deposits with intraperitoneal chemotherapy to address remaining microscopic disease. By delivering chemotherapy intraperitoneally, drug exposure to the peritoneal surface is increased 20-fold compared to systemic exposure. Summary Several case studies and a systematic review on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have been published for pseudomysoma peritonei. Although no randomized trials or comparative studies have been published, the data have shown consistent, long-term disease free survival and overall survival with the use of this technique as compared to historic controls. Numerous studies of peritoneal carcinomatosis from colorectal cancer with different levels of evidence support the safety and feasibility of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Existing data suggest a possible improvement in long-term survival of select patients. However, prospective randomized trials are needed to compare best available systemic therapy with and without cytoreductive surgery and hyperthermic intraperitoneal chemotherapy to determine the exact effects of each step, which are currently unknown. An ongoing Phase III trial (NCT ) addresses this question of how much of the survival benefit is derived from the cytoreduction and how much from hyperthermic intraperitoneal chemotherapy, as patients will be randomly assigned to hyperthermic intraperitoneal chemotherapy or no hyperthermic intraperitoneal chemotherapy after complete cytoreductive surgery. The conventional treatment of peritoneal mesothelioma (diffuse malignant type) has resulted in a median survival of approximately 12 months. Although the data on the use of cytoreductive surgery and perioperative intraperitoneal chemotherapy consists of non-randomized case series without control groups, they have shown a significant prolongation of survival ranging from 29.5 to 92 months. Policy History Date Action 11/2011- Medical policy ICD 10 remediation: Formatting, editing and coding updates. 4/2012 7/2011 Reviewed - Medical Policy Group Hematology and Oncology. 9/2010 Reviewed - Medical Policy Group - Hematology and Oncology. 9/2009 Reviewed - Medical Policy Group - Hematology and Oncology. 10/2008 Reviewed - Medical Policy Group Hematology and Oncology. 3/1/2008 Medical Policy 048 effective 3/1/2008 describing covered and non-covered indications Information Pertaining to All Blue Cross Blue Shield Medical Policies Click on any of the following terms to access the relevant information: Medical Policy Terms of Use 3

4 Managed Care Guidelines Indemnity/PPO Guidelines Clinical Exception Process Medical Technology Assessment Guidelines References 1. Elias D, Honore C, Ciuchendea R et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg 2008; 95(9): Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol 2011; 103(8): Glockzin G, Ghali N, Lang SA et al. Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. J Surg Oncol 2009; 100(4): Glehen O, Gilly FN, Boutitie F et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Cancer 2010; 116(24): Elias D, Gilly F, Quenet F et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2010; 36(5): Vaira M, Cioppa T, de Marco G et al. Management of pseudomyxoma peritonei by cytoreduction + HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience. In Vivo 2009; 23(4): Chua TC, Yan TD, Smigielski ME et al. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 2009; 16(7): Yan TD, Black D, Savady R et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007; 14(2): Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 2010; 36(7): Rampone B, Schiavone B, Martino A et al. Current role of hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from colorectal cancer. World J Gastroenterol 2010: 16(11): Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21(20): Verwaal VJ, Bruin S, Boot H et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 5(9): Mahteme H, Hansson J, Berglund A et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer 2004; 90(2): Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2008; 27(5): Levine EA. The randomized trial of cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion: what it does and does not tell us. Ann Surg Oncol 2008; 15(10):

5 16. Markman M. Intraperitoneal hyperthermic chemotherapy as treatment of peritoneal carcinomatosis of colorectal cancer. Letter to the editor. J Clin Oncol 2004; 22(8): McQuellon RP, Loggie BW, Fleming RA et al. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Clin Oncol 2001; 27(1): vanleeuwen BL, Graf W, Pahlman L et al. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol 2008; 15: Glehen O, Kwiatkowski F, Sugarbaker PH et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22(16): Yan TD, Deraco M, Baratti D et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; 27(36): National Comprehensive Cancer Network ( NCCN). Colon cancer (V ). Available online at: Last accessed September Esquivel J, Sticca R, Sugarbaker P et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007; 14(1):

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)

INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) MEDICAL POLICY INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: CS141.A Effective Date: September 1, 2015 Table of Contents COVERAGE RATIONALE DEFINITIONS... APPLICABLE CODES..

More information

Comments: Policy Accepted during 2013 Annual Review with no changes.

Comments: Policy Accepted during 2013 Annual Review with no changes. Health Plan Coverage Policy ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 09/18/2013 Title: Cytoreduction Surgery with Hyperthermic Intraperitoneal Chemotherapy Comments: Policy

More information

Peritoneal Surface Malignancies. Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA

Peritoneal Surface Malignancies. Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA Peritoneal Surface Malignancies Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA Cancer dissemination routes Hematogenous metastases Lymphatic metastases Implants on peritoneal surfaces Surgically

More information

Protocol. Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

Protocol. Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies (20307) (Formerly Chemotherapy for the Treatment of Pseudomyxoma Peritonei, Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2016 3/2017

More information

Rachel E. Kirby, Jing Zhao, Terence Chua, Winston Liauw and David L. Morris *

Rachel E. Kirby, Jing Zhao, Terence Chua, Winston Liauw and David L. Morris * Send Orders for Reprints to reprints@benthamscience.net The Open Surgical Oncology Journal, 2014, 5, 1-5 1 Open Access Avoidance of Early Post-Operative Intraperitoneal Chemotherapy (EPIC) Following Peritonectomy

More information

Chirurgia Avanzata Del Carcinoma Ovarico Nuove Strategie A Confronto Ovarian Cancer Advanced Surgery New Strategies in Comparison

Chirurgia Avanzata Del Carcinoma Ovarico Nuove Strategie A Confronto Ovarian Cancer Advanced Surgery New Strategies in Comparison Peritoneal dissection and intraperitoneal chemotherapy under hyperthermic conditions. If you select the right patients long-term survival can be achieved. Chirurgia Avanzata Del Carcinoma Ovarico Nuove

More information

Clinical Commissioning Policy: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma

Clinical Commissioning Policy: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma Clinical Commissioning Policy: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma Reference: NHS England B03/P/a 1 Information Reader Box (IRB) to be inserted

More information

Cigna Medical Coverage Policy

Cigna Medical Coverage Policy Cigna Medical Coverage Policy Subject Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 8 References... 8 Effective

More information

Luis D. Carcorze Soto, MD PGY-3

Luis D. Carcorze Soto, MD PGY-3 Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:

More information

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as Part of an Integrative Treatment Plan for Colorectal Peritoneal Carcinomatosis

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as Part of an Integrative Treatment Plan for Colorectal Peritoneal Carcinomatosis Hyperthermic Intraperitoneal Chemotherapy (HIPEC) as Part of an Integrative Treatment Plan for Colorectal Peritoneal Carcinomatosis T. Christopher Windham, M.D., F.A.C.S. Medical Director, Florida Hospital

More information

Clinical Commissioning Policy: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma

Clinical Commissioning Policy: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma Clinical Commissioning Policy: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma Reference: NHS England A08/P/c 2 NHS England INFORMATION READER BOX Directorate

More information

Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD

Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD KCHC 8/29/13 52 y.o. F presented with severe pain in the right back and right flank, sharp, 8 out of 10, for 7 days.

More information

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy: Indications, Aims, and Results: A Systematic Review of the Literature

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy: Indications, Aims, and Results: A Systematic Review of the Literature Ann Surg Oncol DOI 10.1245/s10434-012-2360-0 ORIGINAL ARTICLE REVIEW ARTICLE Laparoscopic Hyperthermic Intra Chemotherapy: Indications, Aims, and Results: A Systematic Review of the Literature Enrico Facchiano,

More information

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future Mazin Al-kasspooles, MD Associate Professor of Surgery Division of Surgical Oncology Director, Regional Therapy

More information

Protocol. Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies

Protocol. Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies (20307) Medical Benefit Effective Date: 07/01/15 Next Review Date: 03/17 Preauthorization Yes Review Dates: 01/11, 01/12, 01/13, 01/14, 01/15,

More information

Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS

Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum

More information

Behavioral Health Policy Phototherapy Light for the Treatment of Seasonal Affective (SAD) and Other Depressive Disorders

Behavioral Health Policy Phototherapy Light for the Treatment of Seasonal Affective (SAD) and Other Depressive Disorders Behavioral Health Policy Phototherapy Light for the Treatment of Seasonal Affective (SAD) and Other Depressive Disorders Table of Contents Policy: Commercial Coding Information Information Pertaining to

More information

Yue Zhu, Nader Hanna, Cherif Boutros, H. Richard Alexander Jr. Background

Yue Zhu, Nader Hanna, Cherif Boutros, H. Richard Alexander Jr. Background Review Article Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases Yue

More information

Peritoneal Carcinomatosis: Pathophysiology, Prevention, and Treatment

Peritoneal Carcinomatosis: Pathophysiology, Prevention, and Treatment Peritoneal Carcinomatosis: Pathophysiology, Prevention, and Treatment Wim Ceelen, MD, PhD, FACS GI Surgery, UZ Gent KAGB 27/4/2013 Overview What is peritoneal carcinomatosis? Rationale for IP drug delivery

More information

A succesfull case of HIPEC in a peritoneal mesothelioma patient

A succesfull case of HIPEC in a peritoneal mesothelioma patient A succesfull case of HIPEC in a peritoneal mesothelioma patient Firmino, NLJ¹²; Miranda, E¹³; Oliveira, DA ²; Lima, MBA ¹²; Diniz, AF ¹²; Gomes, GES ¹²; Azevedo, LW ¹²; Soares,MC¹²; Gomes, ASA³. ¹Pernambuco

More information

Perioperative Intraperitoneal Chemotherapy. Annals of surgical oncology 17.9 (2010): 2370 7. Web. 17 Jan. 2015.

Perioperative Intraperitoneal Chemotherapy. Annals of surgical oncology 17.9 (2010): 2370 7. Web. 17 Jan. 2015. Alexander, H Richard et al. Treatment Factors Associated with Long-Term Survival after Cytoreductive Surgery and Regional Chemotherapy for Patients with Malignant Peritoneal Mesothelioma. Surgery 153.6

More information

Clinical Commissioning Policy: Cytoreduction surgery for patients with peritoneal carcinomatosis April 2013. Reference : NHSCB/A08/P/a

Clinical Commissioning Policy: Cytoreduction surgery for patients with peritoneal carcinomatosis April 2013. Reference : NHSCB/A08/P/a Clinical Commissioning Policy: Cytoreduction surgery for patients with peritoneal carcinomatosis April 2013 Reference : NHS Commissioning Board Clinical Commissioning Policy for Cytoreduction surgery for

More information

Cytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface

Cytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface J. Exp. Clin. Cancer Res., 22, 4, 2003 - Supplement Cytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface Malignancy Yan T.D., Esquivel J., Carmignani

More information

National Medical Policy

National Medical Policy National Medical Policy Subject: Policy Number: Intraperitoneal Hyperthermic Chemotherapy for Abdominopelvic Cancers NMP346 Effective Date*: June 2007 Updated: November 2014 This National Medical Policy

More information

INTRODUCTION. Abstract Background. 3 Centre hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bé

INTRODUCTION. Abstract Background. 3 Centre hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bé Childbearing after hyperthermic intraperitoneal chemotherapy: results from an international survey Pablo Ortega-Deballon 1 2 *, Olivier Glehen 3, Edward Levine 4, Pompiliu Piso, Paul H. Sugarbaker 6, Andrea

More information

INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS

INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS Description of Treatment A major difficulty in treating

More information

J Clin Oncol 27:6237-6242. 2009 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 27:6237-6242. 2009 by American Society of Clinical Oncology INTRODUCTION VOLUME 27 NUMBER 36 DECEMBER 20 2009 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma:

More information

IN MANY PATIENTS WITH ABDOMINAL OR PELVIC MALIGNANCIES, surgical treatment

IN MANY PATIENTS WITH ABDOMINAL OR PELVIC MALIGNANCIES, surgical treatment Sugarbaker, Cancerología 3 (2008): 119-124 1 Washington Cancer Institute, Washington, DC, USA Overview of Peritoneal Carcinomatosis Paul H. Sugarbaker 1 Abstract IN MANY PATIENTS WITH ABDOMINAL OR PELVIC

More information

Selection of patients and staging of peritoneal surface malignancies

Selection of patients and staging of peritoneal surface malignancies Online Submissions: http://www.wjgnet.com/1948-5204office wjgo@wjgnet.com doi:10.4251/wjgo.v2.i1.31 World J Gastrointest Oncol 2010 January 15; 2(1): 31-35 ISSN 1948-5204 (online) 2010 Baishideng. All

More information

Pseudomyxoma Peritonei Where are we in 2014?

Pseudomyxoma Peritonei Where are we in 2014? Pseudomyxoma Peritonei Where are we in 2014? Santiago González-Moreno, MD, PhD Head, Department of GI Surgical Oncology Peritoneal Surface Oncology Program Medical Director * * * * * * * * * * * * French

More information

National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28)

National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28) National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28) Tracking Information Publication Number Manual Section Number 100-3 190.28 Manual Section Title Tumor Antigen by

More information

Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction

Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction Table of Contents Policy: Commercial Coding Information Information Pertaining

More information

MEDICAL POLICY SUBJECT: HYPERTHERMIA AS A CANCER TREATMENT. POLICY NUMBER: 2.01.25 CATEGORY: Technology Assessment

MEDICAL POLICY SUBJECT: HYPERTHERMIA AS A CANCER TREATMENT. POLICY NUMBER: 2.01.25 CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: HYPERTHERMIA AS A CANCER PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland

More information

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly Huang et al. World Journal of Surgical Oncology (2015) 13:262 DOI 10.1186/s12957-015-0682-7 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Cytoreductive surgery and perioperative intraperitoneal chemotherapy

More information

Effects of sex hormones on survival of peritoneal mesothelioma

Effects of sex hormones on survival of peritoneal mesothelioma Huang et al. World Journal of Surgical Oncology (2015) 13:210 DOI 10.1186/s12957-015-0624-4 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Effects of sex hormones on survival of peritoneal mesothelioma

More information

Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure

Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure Eddy Cotte, Brigitte Tranchand, Annie-Claude Beaujard, François-Noël

More information

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI

More information

Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma

Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma Original article Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma T. C. Chua 1,T.D.Yan 1,2, M. Deraco 3,O.Glehen 4,B.J.Moran 5 and P. H. Sugarbaker 6,onbehalf

More information

Peritoneal tumour service. Information for patients

Peritoneal tumour service. Information for patients Peritoneal tumour service Hyperthermic intraperitoneal chemotherapy (HIPEC) Information for patients Chemotherapy given into the abdomen during surgery is called intraoperative chemotherapy. This information

More information

O. Glehen 1,2, E. Cotte 1,2, J. C. Lifante 1,2, C. Arvieux 2,3, N. Moles 1, C. Brigand 2,4, A. C. Beaujard 1,2, Y. François 1,2, F. N.

O. Glehen 1,2, E. Cotte 1,2, J. C. Lifante 1,2, C. Arvieux 2,3, N. Moles 1, C. Brigand 2,4, A. C. Beaujard 1,2, Y. François 1,2, F. N. Acta chir belg, 2006, 106, 285-290 Peritoneal Carcinomatosis in Digestive Cancers : Cytoreductive Surgery Combined with Intraperitoneal Chemohyperthermia. The Experience in Centre Hospitalier et Universitaire

More information

Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation

Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation Volume 2013, Article ID 198729, 4 pages http://dx.doi.org/10.1155/2013/198729 Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation R. F. Falkenstern-Ge,

More information

Mesothelioma: Questions and Answers

Mesothelioma: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

Omental mesothelioma as a diagnostic and therapeutic challenge: A case report

Omental mesothelioma as a diagnostic and therapeutic challenge: A case report www.edoriumjournals.com Case in Images OPEN ACCESS Omental mesothelioma as a diagnostic and therapeutic challenge: A case report Cihan Akgul Ozmen, Yekta Tuzun, Hatice Ozturkmen Akay, Hasan Nazaroglu ABSTRACT

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Eur Respir J 2012; 40: 185 189 DOI: 10.1183/09031936.00153611 CopyrightßERS 2012 Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Ronald A.M. Damhuis*, Caroline

More information

Management of peritoneal surface malignancy: a review of the recent literature

Management of peritoneal surface malignancy: a review of the recent literature JBUON 2014; 19(3): 618-626 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Management of peritoneal surface malignancy: a review of the recent literature

More information

Clinical Policy Bulletin: Hyperthermia in Cancer Therapy

Clinical Policy Bulletin: Hyperthermia in Cancer Therapy Hyperthermia in Cancer Therapy Page 1 of 28 Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Clinical Policy Bulletin: Hyperthermia in Cancer Therapy Number:

More information

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma Original Article 291 Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma Grace HC Tan, 1 MBBS (London), MRCS (Edinburgh), Michelle Cheung, 1 MBBCh

More information

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) 2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Wednesday Oct 7th, 2015 Congress Center (Hörsaal 1 3) Marien Hospital Herne Accreditation by the Medical Chamber

More information

Evidence-Based Medicine in the Treatment of Peritoneal Carcinomatosis: Past, Present, and Future

Evidence-Based Medicine in the Treatment of Peritoneal Carcinomatosis: Past, Present, and Future 2009;100:335 344 Evidence-Based Medicine in the Treatment of Peritoneal Carcinomatosis: Past, Present, and Future AVIRAM NISSAN, MD, 1,2 * ALEXANDER STOJADINOVIC, MD, 3,4 ALFREDO GAROFALO, MD, 5{ JESUS

More information

Peritoneal Carcinosis

Peritoneal Carcinosis Peritoneal Carcinosis What is it and how to cure it Peritoneum Peritoneum is a thin and transparent membrane that covers the internal part of the abdominal and pelvic cavity and all the viscera contained

More information

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063

J of Evidence Based Med & Hlthcare, pissn- 2349-2562, eissn- 2349-2570/ Vol. 2/Issue 33/Aug. 17, 2015 Page 5063 PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia

Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia Online Submissions: http://www.wjgnet.com/1948-5204office wjgo@wjgnet.com doi:10.4251/wjgo.v3.i12.169 World J Gastrointest Oncol 2011 December 15; 3(12): 169-174 ISSN 1948-5204 (online) 2011 Baishideng.

More information

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced

More information

ESSO Course on Peritoneal Surface Malignancy

ESSO Course on Peritoneal Surface Malignancy ESSO Course on Peritoneal Surface Malignancy In partnership with The Christie School of Oncology 08-09 October 2015 MANCHESTER (UK) ESSO Course on Peritoneal Surface Malignancy Chair: Sarah O Dwyer, The

More information

Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures

Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures Online Submissions: http://www.wjgnet.com/1948-9366office wjgs@wjgnet.com doi:10.4240/wjgs.v4.i4.87 World J Gastrointest Surg 2012 April 27; 4(4): 87-95 ISSN 1948-9366 (online) 2012 Baishideng. All rights

More information

Ching-Yao Yang, Yu-Wen Tien

Ching-Yao Yang, Yu-Wen Tien Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT

MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT Written by: Karyn Varley MS, SCT(ASCP) The donating laboratory would like to remain anonymous. PATIENT HISTORY 28 year old female Lived

More information

Oncologist. The. Clinical Pharmacology. Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy

Oncologist. The. Clinical Pharmacology. Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy The Oncologist Clinical Pharmacology Update on Chemotherapeutic Agents Utilized for Perioperative Intraperitoneal Chemotherapy PAUL H. SUGARBAKER, a JORGE TORRES MORA, b PABLO CARMIGNANI, a O. ANTHONY

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information

Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective Date: 10/1/2013

Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective Date: 10/1/2013 Moda Health Plan, Inc. Medical Necessity Criteria Subject: Alimta (pemetrexed) Page 1 of 6 Origination Date: 08/13 Revision Date(s): 12/13, 12/14, 04/2015 Developed By: Medical Criteria Committee Effective

More information

Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required]

Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required] Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required] Medical Policy: MP-SU-01-11 Original Effective Date: February 24, 2011 Reviewed: Revised: This policy applies

More information

CANCERS OF THE PERITONEUM PERITONEAL MESOTHELIOMA PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES

CANCERS OF THE PERITONEUM PERITONEAL MESOTHELIOMA PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES CANCERS OF THE PERITONEUM PERITONEAL MESOTHELIOMA PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES Coordinator: Alex Kartheuser (Colorectal Surgery, Cliniques universitaires St-Luc, UCL) Authors

More information

Multicystic Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Multicystic Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Multicystic Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) D. BARATTI 1, S. KUSAMURA 1, A. SIRONI 2, A. CABRAS 3, L. FUMAGALLI 4, B. LATERZA

More information

Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy

Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy 00. Elsevier Masson SAS. Tous droits réservés Gastroenterol Clin Biol 00;:- MÉSOTHÉLIOMES MALINS DU PÉRITOINE ARTICLE ORIGINAL Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery

More information

Highly Specialised Services. Peritoneal Oncology Service. Report September 2015

Highly Specialised Services. Peritoneal Oncology Service. Report September 2015 Highly Specialised Services Peritoneal Oncology Service Report September 2015 The Christie NHS Foundation Trust Wilmslow Road Withington Manchester M20 4BX http://www.christie.nhs.uk/our-services/colorectal-and-peritoneal-oncology-centre

More information

Status Active. Assistant Surgeons. This policy addresses reimbursement for assistant surgical procedures during the same operative session.

Status Active. Assistant Surgeons. This policy addresses reimbursement for assistant surgical procedures during the same operative session. Status Active Reimbursement Policy Section: Surgery/Interventional Procedure Policy Number: RP - Surgery/Interventional Procedure - 001 Assistant Surgeons Effective Date: June 1, 2015 Assistant Surgeons

More information

WellPoint Cancer Care Quality Program Provider FAQs

WellPoint Cancer Care Quality Program Provider FAQs WellPoint Cancer Care Quality Program Provider FAQs WellPoint Cancer Care Quality Program What is the WellPoint Cancer Care Quality Program? Anthem Blue Cross and Blue Shield (Anthem) is pleased to bring

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Medical Policy Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds

Medical Policy Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds Medical Policy Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy:

More information

P L E U R A L M E S O T H E L I O M A

P L E U R A L M E S O T H E L I O M A For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Particularities of anesthesia and postoperative intensive care related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Particularities of anesthesia and postoperative intensive care related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy Particularities of anesthesia and postoperative intensive care related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy P. Piso 1, C. Schmidt 2, C. Wiesenack 2, M. Bucher 2, H. J.

More information

Treatment of Hepatic Neoplasm

Treatment of Hepatic Neoplasm I. Policy University Health Alliance (UHA) will reimburse for treatment of hepatic neoplasm outside of systemic chemotherapy alone when determined to be medically necessary and within the medical criteria

More information

MEDICAL POLICY POLICY TITLE DENTAL AND ORAL SURGERY SERVICES AFTER AN ACCIDENT POLICY NUMBER MP- 1.108

MEDICAL POLICY POLICY TITLE DENTAL AND ORAL SURGERY SERVICES AFTER AN ACCIDENT POLICY NUMBER MP- 1.108 Original Issue Date (Created): July 1, 2005 Most Recent Review Date (Revised): Effective Date: June 29, 2010 May 25, 2011- RETIRED I. POLICY II. Dental and/or oral surgery services (on a limited basis)

More information

Accepted Manuscript. 10.1016/j.ejso.2010.08.130. Reference: YEJSO 3033. To appear in: European Journal of Surgical Oncology

Accepted Manuscript. 10.1016/j.ejso.2010.08.130. Reference: YEJSO 3033. To appear in: European Journal of Surgical Oncology Accepted Manuscript Title: Multicystic Peritoneal Mesothelioma: Outcomes and Patho-Biological Features in a Multi-Institutional Series Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal

More information

Cancer Treatment Reviews

Cancer Treatment Reviews Cancer Treatment Reviews 38 (2012) 605 612 Contents lists available at SciVerse ScienceDirect Cancer Treatment Reviews journal homepage: www.elsevierhealth.com/journals/ctrv Anti-Tumour Treatment Diffuse

More information

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University

More information

Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present and future

Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present and future Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present and future Aviram Nissan 1, Alexander Stojadinovic 2, Alfredo Garofalo 3, Jesus Esquivel 4, Pompiliu Piso 5 From: 1.

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Survey of Mesothelioma Associated with Asbestos Exposure in Japan The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

More information

Treating Mesothelioma - A Quick Guide

Treating Mesothelioma - A Quick Guide Treating Mesothelioma - A Quick Guide Contents This is a brief summary of the information on Treating mesothelioma from CancerHelp UK. You will find more detailed information on the website. In this information

More information

Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer

Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Policy Number: Original Effective Date: MM.07.014 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 01/23/2015 Section:

More information

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Peritoneal Mesothelioma: The Columbia Experience

Peritoneal Mesothelioma: The Columbia Experience 48 Peritoneal Mesothelioma: The Columbia Experience Jennifer A. Wagmiller, Mary-Louise Keohan, John A. Chabot, Karen Fountain, Mary Hesdorffer, and Robert N. Taub Malignant peritoneal mesothelioma is a

More information

Surgical therapy of. who should be operated

Surgical therapy of. who should be operated SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich

More information

Coverage Analysis: The Cornerstone of Clinical Research Billing Presented by: Mary L. Veazie, CPA, MBA, CHC, CHRC Executive Director, Clinical

Coverage Analysis: The Cornerstone of Clinical Research Billing Presented by: Mary L. Veazie, CPA, MBA, CHC, CHRC Executive Director, Clinical Coverage Analysis: The Cornerstone of Clinical Research Billing Presented by: Mary L. Veazie, CPA, MBA, CHC, CHRC Executive Director, Clinical Research Finance The University of Texas MD Anderson Cancer

More information

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)

More information

MEDICAL POLICY POLICY TITLE

MEDICAL POLICY POLICY TITLE Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): Effective Date: April 15, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND High dose chemotherapy (HDC) involves the administration

More information

Quick Facts about Appendix Cancer

Quick Facts about Appendix Cancer Quick Facts about Appendix Cancer What is the appendix? The appendix is a pouch-like tube attached to the first part of the large intestine (cecum). The appendix is about 10 centimetres long and has no

More information